Elanco Animal Health Incorporated (NYSE:ELAN) Holdings Lifted by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. grew its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 162.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,374,464 shares of the company's stock after acquiring an additional 849,977 shares during the quarter. Jupiter Asset Management Ltd. owned about 0.28% of Elanco Animal Health worth $16,645,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. AM Squared Ltd bought a new stake in Elanco Animal Health in the 3rd quarter valued at about $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $35,000. Farther Finance Advisors LLC raised its holdings in shares of Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company's stock valued at $49,000 after buying an additional 2,044 shares during the last quarter. Venturi Wealth Management LLC boosted its position in shares of Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company's stock worth $50,000 after buying an additional 1,601 shares during the period. Finally, Jones Financial Companies Lllp boosted its position in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after buying an additional 2,059 shares during the period. Institutional investors own 97.48% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on ELAN. UBS Group lowered their target price on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Barclays lowered their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Leerink Partners started coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price objective for the company. Morgan Stanley decreased their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Finally, Piper Sandler dropped their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $15.17.

Remove Ads

Elanco Animal Health Price Performance

ELAN stock traded up $0.16 during trading hours on Friday, hitting $10.47. 4,680,857 shares of the stock traded hands, compared to its average volume of 4,674,860. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock has a 50-day simple moving average of $11.46 and a 200 day simple moving average of $12.75. Elanco Animal Health Incorporated has a one year low of $10.03 and a one year high of $18.80. The company has a market cap of $5.18 billion, a P/E ratio of 26.16, a P/E/G ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the firm earned $0.08 EPS. The business's revenue for the quarter was down 1.4% on a year-over-year basis. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the acquisition, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.57% of the stock is owned by corporate insiders.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.